Christian Borel

3.2k total citations
78 papers, 1.9k citations indexed

About

Christian Borel is a scholar working on Oncology, Otorhinolaryngology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Christian Borel has authored 78 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Oncology, 36 papers in Otorhinolaryngology and 30 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Christian Borel's work include Head and Neck Cancer Studies (36 papers), Lung Cancer Treatments and Mutations (15 papers) and Cancer Immunotherapy and Biomarkers (12 papers). Christian Borel is often cited by papers focused on Head and Neck Cancer Studies (36 papers), Lung Cancer Treatments and Mutations (15 papers) and Cancer Immunotherapy and Biomarkers (12 papers). Christian Borel collaborates with scholars based in France, United States and Belgium. Christian Borel's co-authors include Michel Velten, Thierry Petit, P Haegèle, J F Rodier, L Thill, Claude Soubrane, Olivier Rixe, G. Bronner, H. Flesch and E Antoine and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Christian Borel

76 papers receiving 1.9k citations

Peers

Countries citing papers authored by Christian Borel

Since Specialization

Citations

This map shows the geographic impact of Christian Borel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christian Borel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christian Borel more than expected).

Fields of papers citing papers by Christian Borel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christian Borel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christian Borel. The network helps show where Christian Borel may publish in the future.

Co-authorship network of co-authors of Christian Borel

This figure shows the co-authorship network connecting the top 25 collaborators of Christian Borel. A scholar is included among the top collaborators of Christian Borel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christian Borel. Christian Borel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial 2024 ·Radiotherapy and Oncology ·Christian Borel, Xu-Shan Sun, Alexandre Coutté, G. Béra, Christian Sire, Sylvie Zanetta, M. Alfonsi, (unknown), Thierry Chatellier, (unknown), (unknown), (unknown), (unknown), Nelly Étienne-Selloum, (unknown), (unknown), Michel Velten, Jean‐Pierre Pignon, (unknown), Jean Bourhis	2
2	Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study 2023 ·BMC Cancer ·(unknown), L. Collet, (unknown), Christian Borel, Magalie P. Tardy, F. Huguet, Sandrine Richard, Sébastien Salas, Esma Saâda-Bouzid, Jérôme Fayette, Amaury Daste	3
3	758P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic vulvar and vaginal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial 2023 ·Annals of Oncology ·(unknown), Cyril Abdeddaim, (unknown), Sophie Cousin, Carlos Gomez‐Roca, Christian Borel, François Ghiringhelli, Damien Vansteene, Frédéric Bigot, Emmanuelle Jeannot, (unknown), Gianmaria Frigè, Luca Mazzarella, (unknown), (unknown), Marta Jimenez, (unknown), Maud Kamal, Bastien Cabarrou, Christophe Le Tourneau	1
4	NISCAHN: a phase II trial of nivolumab in patients with salivary gland carcinoma (Unicancer ORL-08) 2023 ·SHILAP Revista de lepidopterología ·Jérôme Fayette, Caroline Even, Laurence Digue, Lionnel Geoffrois, Frédéric Rolland, Didier Cupissol, J. Guigay, Christophe Le Tourneau, (unknown), Sylvie Zanetta, Laurence Bozec, Christian Borel, (unknown), Valérie Costes‐Martineau, (unknown), (unknown), (unknown), Audrey Lardy-Cléaud, Sylvie Chabaud	6
5	752P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic squamous cell cervix carcinoma: Subgroup analysis of the PEVOsq basket trial 2023 ·Annals of Oncology ·(unknown), Christian Borel, François Ghiringhelli, Frédéric Bigot, Damien Vansteene, (unknown), Sophie Cousin, Xavier Durando, Elodie Coquan, Cyril Abdeddaim, Emmanuelle Jeannot, (unknown), Gianmaria Frigè, (unknown), (unknown), Maud Kamal, (unknown), Marta Jimenez, Bastien Cabarrou, Christophe Le Tourneau	1
6	Dynamic profiling of immune microenvironment during anti-PD-1 immunotherapy for head and neck squamous cell carcinoma: the IPRICE study 2023 ·BMC Cancer ·(unknown), (unknown), (unknown), Christian Borel, (unknown), (unknown), Philippe Schultz, (unknown), Alain C. Jung, Sophie Martin, (unknown)	1
7	The EXTREME Regimen Associating Cetuximab and Cisplatin Favors Head and Neck Cancer Cell Death and Immunogenicity with the Induction of an Anti-Cancer Immune Response 2022 ·Cells ·(unknown), (unknown), (unknown), (unknown), Philippe Schultz, Christian Borel, Erwan Pencreach, Georg Mellitzer, Christian Gaiddon, Alain C. Jung	6
8	Identification of HMGA2 as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer 2022 ·Frontiers in Oncology ·Alexander I. Spira, Ahmad Awada, Nicolás Isambert, David Lorente, Nicolas Penel, Yue Zhang, Laureen S. Ojalvo, Christine Hicking, P. Alexander Rolfe, Christian Ihling, Isabelle Dussault, (unknown), Christian Borel	5
9	Cav1/EREG/YAP Axis in the Treatment Resistance of Cav1-Expressing Head and Neck Squamous Cell Carcinoma 2021 ·Cancers ·(unknown), (unknown), (unknown), Sophie Foppolo, Véronique Bruban, Nelly Étienne-Selloum, Alain C. Jung, Murielle Masson, (unknown), (unknown), Hélène Burckel, Carole Mura, G. Noël, Christian Borel, (unknown), (unknown), Marie‐Pierre Chenard, (unknown), Monique Dontenwill, Sophie Martin	9
10	Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort 2020 ·Journal for ImmunoTherapy of Cancer ·Byoung Chul Cho, Amaury Daste, Alain Ravaud, Sébastien Salas, Nicolás Isambert, Edward F. McClay, Ahmad Awada, Christian Borel, Laureen S. Ojalvo, Christoph Helwig, P. Alexander Rolfe, James L. Gulley, Nicolas Penel	69
11	930P Weekly paclitaxel, carboplatin and cetuximab (PCC) as first-line treatment of recurrent and/or metastatic head & neck squamous cell carcinoma (R/M-HNSCC) for patients ineligible to cisplatin based chemotherapy 2020 ·Annals of Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Martin Demarchi, Thierry Petit, Christian Borel	1
12	914MO Standard versus fractionated high dose cisplatin concomitant with radiotherapy in locally advanced head & neck squamous cell cancer (LA-HNSCC): Results of the GORTEC 2015-02 CisFRad randomized trial 2020 ·Annals of Oncology ·Christian Borel, Xiangdong Sun, Alexandre Coutté, G. Béra, Sylvie Zanetta, M. Alfonsi, (unknown), Thierry Chatellier, (unknown), (unknown), (unknown), Nelly Étienne-Selloum, (unknown), (unknown), Michel Velten, Jean‐Pierre Pignon, (unknown), Jean Bourhis	4
13	Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial 2020 ·British Journal of Cancer ·(unknown), Thomas Aparicio, Jaafar Bennouna, Karine Le Malicot, Valérie Boige, Julien Taı̈eb, Olivier Bouché, Jean–Marc Phelip, Éric François, Christian Borel, Roger Faroux, Laëtitia Dahan, Jean‐Baptiste Bachet, Joëlle Egreteau, Marie‐Christine Kaminsky, Jean‐Marc Gornet, Oana Cojocarasu, Mohamed Gasmi, Véronique Guerin‐Meyer, Côme Lepage, François Ghiringhelli	4
14	Factors improving the outcome of patients re-irradiated with intensity-modulated radiotherapy (IMRT) for relapse or new head and neck cancer developed in irradiated areas 2018 ·Chinese Clinical Oncology ·(unknown), D. Antoni, François Lefèbvre, (unknown), Philippe Schultz, (unknown), Christian Borel, G. Noël	9
15	Any place left for induction chemotherapy for locally advanced head and neck squamous cell carcinoma? 2018 ·Anti-Cancer Drugs ·(unknown), Julie Leblanc, Christian Borel	2
16	Cetuximab-Carboplatin-5-Fluorouracil Regimen in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A French Retrospective Survey 2017 ·Oncology ·(unknown), Philippe Barthélémy, François Lefèvre, Agnès Dupret‐Bories, (unknown), Clément Korenbaum, H. Flesch, G. Bronner, Christian Borel	8
17	Pazopanib in patients with progressive recurrent or metastatic (R/M) salivary gland carcinoma (SGC): Further evaluation of efficacy including tumor growth rates (GR) analysis. H&N Unicancer Group PACSA trial with the REFCOR 2016 ·Annals of Oncology ·J. Guigay, François Bidault, Jérôme Fayette, Caroline Even, Didier Cupissol, Frédéric Rolland, Frédéric Peyrade, Brigitte Laguerre, Christophe Le Tourneau, Sylvie Zanetta, L. Bozec Le Moal, Christian Borel, Laurence Digue, (unknown), (unknown), Valérie Costes, A. Aupérin, Laurence Faivre	1
18	Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. 2001 ·PubMed ·Thierry Petit, Christian Borel, (unknown), J F Rodier, Alexandre Escande, (unknown), P Haegèle	65
19	Carcinoma of an unknown primary site: A chemotherapy strategy based on histological differentiation – results of a prospective study 2001 ·Annals of Oncology ·Mahasti Saghatchian, Karim Fizazi, Christian Borel, Michel Ducreux, (unknown), Thierry Le Chevalier, C Théodore	32
20	Complete remission seven years after treatment for metastatic malignant melanoma 1996 ·Cancer ·Thierry Petit, Christian Borel, Olivier Rixe, Marie‐Françoise Avril, Alain Monnier, B. Giroux, Marise Weil, David Khayat	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact